Abstracts

2020


2019


- Parulekar WR, Joy AA, Gelmon K, Mates M, Desbiens C, Clemons M, Taylor S, Lemieux J, Bartlett J, Whelan T, Ayoub J-P, Cescon D, Bordeleau L, Rahim Y, Winch C, Chen BE. Randomized phase II study comparing two different schedules of palbociclib plus second line endocrine therapy in women with estrogen receptor positive, HER2


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


2017


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)

Clin Oncol 35[Suppl; abstr e14637]. 2017.


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


• Cheung WY, Mittmann N, Leighl NB, Cheung MC, Bradbury PA, Ng RCH, Chen BE, Ding K, Pater JL, Tu D, Hay AE. The economic impact of the transition from branded to generic oncology drugs. J Clin Oncol 34[Suppl; abstr 6520]. 2016.


Bosse D, Mercer J, Raissouni S, Dennis K, Goodwin RA, Jiang M, Powell ED, Kumar A, Lee-Ying RM, Price Hillier JA, Chin Heng DY, Tang PA, MacLean A, Cheung WY, Vickers MM. PROSPECT eligibility and clinical outcomes: Results from the pan-
Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)

Canadian rectal cancer consortium. J Clin Oncol 33[suppl; abstr 6594].


- Parimi S, Karachiwala H, Lin Y, Monzon JG, Tam VC, Chen EX, Dancey J, Tang PA. Critical assessment of phase 0 (Ph0) and window of opportunity (WOO) trials: Definitions and reporting. J Clin Oncol 33[suppl; abstr e17710].
- Penniment MG. Full report of the TROG 03.01, NCIC CTG ES2 multinational phase III study in advanced esophageal cancer comparing palliation of dysphagia and quality of life in patients treated with radiotherapy or chemoradiotherapy. J Clin Oncol 33[(suppl 3; abstr 6)]. 2015.


2014


- Booth CM, Vardy JL, Gill S, Jonker DJ, O’Callaghan CJ, Friedenreich C, Meyer RM,


Piccart-Gebhart MJ, Holmes AP, Baselga J, de Azambuja E, Dueck AC, Viale G,
Zujewski JA, Goldhirsch A, Santillana S, Pritchard KI, Wolff AC, Jackisch C, Lang I, Untch M, Smith IE, Boyle F, Xu B, Gomez HL, Gelber RD, Perez EA. First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC). J Clin Oncol 32:5s[suppl; abstr LBA4]. 2014.


- Moy B, Tu D, Richardson H, Maunsell E, Goss PE. NCIC CTG MAP.3: Symptoms and quality of life (QoL) among racial/ethnic minority women taking the aromatase inhibitor (AI) exemestane (EXE) for breast cancer risk reduction. J Clin Oncol 31[Suppl; abstr 6557], 2013.


- Renouf DJ, Parulekar W, Grigorieva J, Tu D, Moore MJ. Assessment of the association of the VeriStrat test with outcomes in patients (pts) with advanced pancreatic cancer (PC) treated with gemcitabine (G) with or without erlotinib (E) in the NCIC CTG PA.3 phase III trial. J Clin Oncol 31[suppl; abstr 4061], 2013.


2012


from NCIC CTG PR3 / Medical Research Council MRC PR07 randomized trial. Canadian Assoc Rad Oncol [abstr 184], 2012.

- Eisenhauer EA. Antiangiogenics in ovarian cancer: where are we now? Ann Oncol


Leighl NB, Tsao MS, Ho C, Shepherd FA, Murray N, Goffin J, Nicholas G, Seymour L, Goss GD, Bradbury P. NCIC CTG IND.196: Phase I Study of Foretinib (GSK1363089)
and Erlotinib in Patients with Advanced Pretreated NSCLC. EORTC-NCI-AACR Symposium [abstr 607], 2012.

- Liedke PER, Chavarri-Guerra Y, Shepherd LE, Tu D, Pritchard KI, Goss PE. Vasomotor (VM) and musculoskeletal (MSK) symptoms and association with outcomes on extended adjuvant letrozole therapy: Analyses from NCIC CTG MA.17. J Clin Oncol 30[suppl, abstr 524], 2012.


Steele R, Quirke P, Grieve R, Monson J, Couture J, de Metz C, Pugh C, Nichols L, Thompson LC, Sebag-Montefiore D, on behalf of all investigators MCTUL. Long Term Outcome After Anastomatic Leak and the Impact of Short Course Pre-Operative Radiotherapy - Data from the MRC CRO7 NCIC CO16 trial. 6th European Multidisciplinary Colorectal Cancer Congress, 2012.


• Cuffe S, Graziano S, Bourredjem A, Pignon J-P, Ezzalfani M, Seymour L, Strevel E, Burkes R, Capelletti M, Janne PA, Tsao MN, Shepherd FA. A pooled exploratory analysis of the impact of tumor size and KRAS mutations on survival benefit from adjuvant platinum-based chemotherapy (ACT) in node negative (N0) non-small cell lung cancer (NSCLC). J Thoracic Oncol 6[Suppl 2, abstr O42.01], S462, 2011.


AP, Mayer RJ. Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CRT: Intergroup trial CALGB 80101. J Clin Oncol 29[suppl; abstr 4003]. 2011.

- Huang J, Sargent DJ, Mahoney MR, Shields AF, Chan E, Goldberg RM, Gill S,


- Li X, Chen J, Wu Y, Tu D. Variable selections in the Cox proportional hazards model based on extended bayesian information criteria. 32nd Annual Conference of the International Society for Clinical Biostatistics, 2011.


PA, Schauer C, Reed N, Ferrandina G, Fossati R, Pujade-Lauraine E. Pegylated liposomal doxorubicin and carboplatin (C-PLD) versus paclitaxel and carboplatin (C-P) in platinum-sensitive ovarian cancer (OC) patients (pts): Treatment at recurrence and overall survival (OS) final analysis from CALYPSO phase III GCIG trial. J Clin Oncol 29[suppl; abstr 5052]. 2011.


- Parulekar W, Chen BE, Elliott C, Shepherd LE, Gelmon KA, Pritchard KI, Whelan TJ,


S9704) comparing CHOP ± R for eight cycles to CHOP ± R for six cycles followed by autotransplant for patients with high-intermediate (H-Int) or high IPI grade diffuse aggressive non-Hodgkin's lymphoma (NHL). J Clin Oncol 29[suppl; abstr 8001]. 2011.


Alberts SR, Sargent DJ, Smyrk TC, Shields AF, Chan E, Goldberg RM, Gill S, Kahlenberg MS, Thibodeau SN, Nair S. Adjuvant mFOLFOX6 with or without cetuximab in KRAS wild-type patients with resected stage III colon cancer: Results from NCCTG Intergroup Phase III Trial N0147. J Clin Oncol 28[18s, abstr CRA3507], 2010.


Eisenhauer E. In search of intermediate endpoints. EORTC-NCI-AACR Symposium [abstr 29], 2010.


Hotte SJ, Chen EX, McIntosh L, Hirte HW, Turner S, Jarvi A, Squires MS, Seymour L. NCIC CTG IND.177: Phase I study of AT7519M given as a short infusion twice weekly.
EORTC-NCI-AACR Symposium [abstr 491], 2010.

- Perren T, Swart AM, Pfisterer J, Ledermann J, Lortholary A, Kristensen G, Carey M, Beale P, Cervantes A, Oza A, on behalf of GCIG ICON7 collaborators. ICON7: A phase III randomised Gynaecologic Cancer InterGroup trial of concurrent bevacizumab and chemotherapy followed by maintenance bevacizumab, versus chemotherapy alone in
women with newly diagnosed epithelial ovarian, primary peritoneal or fallopian tube cancer. Ann Oncol 21[Suppl 8, abstr LBA4], viii2, 2010.


2009


Crandall KJ, Buys TPH, Zhu CQ, Strumpf D, Pintillie M, Ding K, Seymour L, Jurisica I, Shepherd FA, Lam WL, Tsao M-S. High resolution genomic analysis of NSCLC reveals regions of DNA copy number gain that may be predictive of benefit from adjuvant


Clin Oncol 27[15s], 2009.


Palmer M, Broxterman J, Shepherd L, Parulekar W. Tracking patients on an intergroup oncology study. It's a snap! Clinical Trials 6, 536, 2009.


- Moy B, Tu D, Shepherd LE, Palmer MJ, Ingle JN, Goss PE. NCIC CTG MA.17: hormone
Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


- Schell AJ, Young I, Hansen C, Chi KN, Taylor S. BRAF mutation status and growth factor receptor expression do not predict baseline factors or outcome in hormone refractory prostate carcinoma. United States and Canadian Academy of Pathology, 2008.


2007

- Bramwell VH, Pritchard KL, Tu D, Tonkin K, Vachhrajani H, Robert J, Arnold A,


• Ding K. Determining the cutoff points for a predictive continuous biomarker with time to event outcome. Proc Joint Statistical Meetings, 2007.


2007.

- O’Brien P, Willman C, Hiltz A, Pater J. Variations in activation times over time and
according to trial type: the NCIC Clinical Trials Group experience. Clinical Trials 4, 2007.


- Shepherd FA, Seymour L, Tsao MS, Ding K, Magoski N, Eisenhauer E, Pater J. From Nihilism To Hope - The impact of NCIC Clinical Trials Group trials of systemic therapy


Tu D. Identification of patients who will benefit from a treatment based on their genetic profiles: Some examples and statistical issues. Workshop on Statistical Analysis of High-Throughput Genetic Data, 2007.


2006


• O’Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Huntsman DG, Bramwell VH, Andruslis I, Pritchard KI. Topoisomerase II alpha protein overexpression has predictive utility in a randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer (NCIC CTG MA.5). Breast Cancer Research and Treatment 100[Suppl 1], S18, 2006.


• Pater JL, Tu D, Ingle JN, Shepherd LE, Goss PE. An evaluation of the early termination of MA.17 extended adjuvant therapy trial. Breast Cancer Treatment and Research 100[Suppl 1], S107, 2006.


---

2005


- Li D. Determinants of sample size and power in equivalence trials that compare binomial outcomes. Clinical Trials 2[Suppl 1], S59, 2005.
- Li D. Can more frequent regular group sequential tests help to make an earlier conclusion in clinical trials? A retrospective evaluation. Clinical Trials 2[Suppl 1], 2005.
- Messerschmidt T, Koski B. Integrating SOPs into a comprehensive website document management system. Clinical Trials 2[Suppl 1], S50, 2005.


Tu D. Nonparametric estimate and confidence intervals for the hazard ratio based on censored data. Clinical Trials 2[Suppl 1], S36, 2005.


• Ding K. Point estimate following group sequential tests. ENAR Int Biometric Soc, 2004.


Kristensen GB, Vergote I, Eisenhauer E, Baekelandt M, Stuart G, Aavall-Lundquist E, del Campo J, Lopez AB, Mirza M, Lorenz E. First line treatment of ovarian/tubal/peritoneal cancer FIGO stage IIb-IV with paclitaxel/carboplatin with or without epirubicin (TEC vs TC). A Gynecologic Cancer Intergroup study of the NSGO, EORTC GCG, and NCIC CTG. Results on progression free survival.


- Tu D, Gou S. A comparison of statistical tests for the interaction of treatment and biomarker in tumour correlative studies. International Biometric Conference in parallel


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)

2003.


- Li D. Tired of defining axis scale for SAS graphs? A solution with an automatic optimizing


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


2002


- Pollak M, Pritchard K, Whelan T, Bowman D, O'Reilly S, Burnell M, Shepherd L,


2001


• Bezjak A, Dixon P, Brundage M, Tu D, Pater J, Palmer M, Leong C, Mulroy L, Wright J,


- Madarnas Y, Fine S, Sawka C, Shepherd L, Tannock I, Tu D, Levine M. Body size, received dose-intensity and myelotoxicity of adjuvant chemotherapy in relation to


4a, 2001.


2000

Abstracts
Published on Canadian Cancer Trials Group (https://www.ctg.queensu.ca)

- Kraut M, Rusch V, Crowley J, Gandara D. Induction chemoradiation plus surgical


- Baker S, Stephenson J, Goetz A, Belanger K, Moore M, Seymour L, Yee L, Chu E, Hunt


1998


Abstracts
Published on Canadian Cancer Trials Group (https://www.ctg.queensu.ca)


1997


- Bodurtha A, Eisenhauer E, Steward W, Rusthoven J, Quirt I, Lohmann R, Wainman N,


1996

- Cripps C, Osoba D, Zee B. Gender differences in responses to the EORTC quality of life


- Zee B. Phase II design for cancer clinical trials using multivariate endpoints. Biometric Society ENAR, 1996.


Lofters C, Zee B. Adding 5 HT3 antagonists to dexamethasone after 24 hours has a minimal effect in preventing delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Eur.J.Can. 31A(suppl.5), 255, 1995.


Lofters W, Zee B. Adding 5HT3 antagonists to dexamethasone after twenty four hours has a minimal effect in preventing delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Supportive Care in Cancer 3(5), 339, 1995.


Muldal A, James K, Wainman N, Eisenhauer E, Bennett K. Response criteria in solid


1994

- Moore M, Erlichman C, Pillon L, Thiessen J, Eisenhauer E. A phase I clinical and


1993

- Cormier Y, Eisenhauer E, Gregg R, Ayoub J, Goss G, Stewart D, Muldal A, Tarasoff P. Gemcitabine: an active new agent in patients with previously untreated small cell lung...


Eisenhauer E, Cormier Y, Gregg R, Stewart D, Muldal A. Gemcitabine is active in
• Pater J, Niezgoda H, Zee B. Validation of the EORTC-QLC -- a comparison with four other instruments in a heterogenous group of cancer patients. Ann.Oncol. 3(Suppl.5), 175, 1992.


1991


Zee B. Assessing quality of life in antiemetic studies: preliminary results. Antiemetics --


1990


1989

• Palmer M, Pater J. Comparison of errors in body surface area and initial doses in five clinical trials (C0.2, C0.3, HD.4, MA.4, OV.8). Controlled Clin. Trials 10(3), 351, 1989.
• Pritchard K, Pater J, Paul N, Paterson AHG, Fine S. Thromboembolic complications


1988

1987


1986

• O'Dwyer P, Eisenhauer E, Hoth D. Deoxycoformycin in lymphoid malignancies, an overview. NCI-EORTC Symposium on New Drugs in Cancer Therapy, 1986.
• Wallenstein S, Patel HI, Willan A. Use of baseline values in the two period two treatment crossover design. Biometric Society ENAR, 1986.

1985

1984


1983

1981